Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

ONTARGET Investigators., Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.

N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317.

2.

Telmisartan prevents cardiovascular events in a broad group of at-risk patients.

Baumhäkel M, Böhm M.

Expert Opin Pharmacother. 2009 Dec;10(18):3113-7. doi: 10.1517/14656560903449231. Review.

PMID:
19925045
3.

Telmisartan in high-risk cardiovascular patients.

Weber MA.

Am J Cardiol. 2010 Jan 4;105(1 Suppl):36A-43A. doi: 10.1016/j.amjcard.2009.10.008. Review.

PMID:
20102972
4.

The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.

Unger T.

Am J Cardiol. 2003 May 22;91(10A):28G-34G. Review.

PMID:
12781906
5.

Telmisartan for the management of patients at high cardiovascular risk.

Ruilope LM.

Curr Med Res Opin. 2011 Aug;27(8):1673-82. doi: 10.1185/03007995.2011.597378. Review.

PMID:
21718097
6.

Recent advances in cardiovascular risk reduction: implications of ONTARGET.

Guthrie R.

Clin Cornerstone. 2009;9 Suppl 3:S18-26. Review.

PMID:
19409352
8.

Renin-angiotensin system blockade and cardiovascular and renal protection.

Hoogwerf BJ.

Am J Cardiol. 2010 Jan 4;105(1 Suppl):30A-5A. doi: 10.1016/j.amjcard.2009.10.009. Review.

PMID:
20102971
9.

From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.

Böhm M, Baumhäkel M, Mahfoud F, Werner C.

Cardiology. 2010;117(3):163-73. doi: 10.1159/000320094. Review.

PMID:
21051889
10.

[Renin-angiotensin-aldosterone system inhibition and cardiovascular protection].

Oğuz A.

Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 6:4-12. Review. Turkish.

11.

Ramipril: a review of its use in the prevention of cardiovascular outcomes.

Warner GT, Perry CM.

Drugs. 2002;62(9):1381-405. Review.

PMID:
12076194
12.

Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.

Wang JG, Pimenta E, Chwallek F.

Vasc Health Risk Manag. 2014 Apr 5;10:189-200. doi: 10.2147/VHRM.S59429. Review.

13.

Clinical trial update: focus on the ONTARGET study.

Fitchett D.

Vasc Health Risk Manag. 2007;3(6):901-8. Review.

14.

Telmisartan for the reduction of cardiovascular morbidity and mortality.

Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G.

Expert Rev Clin Pharmacol. 2011 Mar;4(2):151-61. doi: 10.1586/ecp.10.141. Review.

PMID:
22115399
15.
16.

Spotlight on ramipril in the prevention of cardiovascular outcomes.

Warner GT, Perry CM.

Am J Cardiovasc Drugs. 2003;3(2):113-6. Review.

PMID:
14727938
17.

Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.

Diener HC.

J Hypertens Suppl. 2009 Jul;27(5):S31-6. doi: 10.1097/01.hjh.0000357906.60778.7f. Review.

PMID:
19587553
18.

Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.

Zou Z, Xi GL, Yuan HB, Zhu QF, Shi XY.

J Hum Hypertens. 2009 May;23(5):339-49. doi: 10.1038/jhh.2008.132. Review.

PMID:
18987649
19.

New standards in hypertension and cardiovascular risk management: focus on telmisartan.

Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C.

Vasc Health Risk Manag. 2010 Mar 24;6:113-33. Review.

20.

Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?

Weber M.

J Hypertens Suppl. 2009 Jul;27(5):S9-14. doi: 10.1097/01.hjh.0000357903.93951.73. Review.

PMID:
19587555
Items per page

Supplemental Content

Support Center